These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34930453)

  • 1. Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.
    Voruz S; Blum S; de Leval L; Schoumans J; Solly F; Spertini O
    Biomark Res; 2021 Dec; 9(1):92. PubMed ID: 34930453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
    Dai Y; Luo L; Wei Z; Cheng P; Luo J; Li J
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39046511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics.
    Vakrmanová B; Nováková M; Říha P; Žaliová M; Froňková E; Mejstříková E; Starý J; Hrušák O; Šrámková L
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29779. PubMed ID: 35592935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.
    Prejzner W; Piekoś O; Bełdzińska K; Sadowska-Klasa A; Zarzycka E; Bieniaszewska M; Lewandowski K; Zaucha JM
    Front Oncol; 2023; 13():1228481. PubMed ID: 37941558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation.
    Zhang XY; Dai HP; Zhang L; Liu SN; Dai Y; Wu DP; Tang XW
    Onco Targets Ther; 2021; 14():5197-5204. PubMed ID: 34744437
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study.
    Gong D; Gu J; Zhou K; Huang W
    Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38265376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Zhang Y; Chen H; Song Y; Tan X; Zhao Y; Liu X; Li Z; Yang F; Jiang M; Gao Z; Wu T
    Br J Haematol; 2020 Apr; 189(1):146-152. PubMed ID: 31869864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
    Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.
    Punatar S; Gokarn A; Nayak L; Bonda A; Chichra A; Mirgh S; Bagal B; Tembhare P; Subramanian P; Khattry N
    Am J Blood Res; 2021; 11(5):528-533. PubMed ID: 34824885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient.
    Li X; Zhu H; Sui T; Zhao X; Deng Q
    Cell Transplant; 2022; 31():9636897221132502. PubMed ID: 36278404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.